WSJ: Stryker eyes takeover of Boston Scientific to form $110B company

Nicholas Leider | | Health Exec | Policy & Regulations

Stryker approached Boston Scientific with a takeover bid on Monday, June 11, according to the Wall Street Journal.

Such a deal would combine two of the largest medical device manufacturers into a single company worth an estimated $110 billion. According to the Wall Street Journal, it was unclear if Boston Scientific would be receptive to such a move.

As of 11:10 a.m. (EST), Boston Scientific shares rose 7 percent after the initial WSJ report, while Stryker is trading down 2.7 percent.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Related Content

FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS
FDA issues Class I recall of infusion pump batteries due to risk of burns
When life sciences met artificial intelligence
DEA, HHS extend telehealth controlled substance prescription rule
Public health contrarian RFK Jr. nominated to HHS secretary

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup